Antiangiogenic Drugs in Ovarian Cancer
Author Information
Author(s): Kumaran G C, Jayson G C, Clamp A R
Primary Institution: Department of Medical Oncology, Cancer Research UK and University of Manchester
Hypothesis
Can antiangiogenic treatments improve outcomes in ovarian cancer?
Conclusion
Anti-VEGF drugs, particularly bevacizumab, have shown promising activity in treating chemotherapy-resistant ovarian cancer.
Supporting Evidence
- Bevacizumab has shown exciting single-agent activity in patients with recurrent ovarian cancer.
- Combination therapies with anti-VEGF drugs and chemotherapy are currently being tested in clinical trials.
- VEGF blockade has been shown to inhibit ascites formation and slow tumor growth in animal models.
Takeaway
This study looks at how certain drugs that stop blood vessels from growing can help treat ovarian cancer, which is a serious disease for many women.
Methodology
The article reviews clinical trials and studies on the use of antiangiogenic drugs in ovarian cancer treatment.
Limitations
The study highlights the need for better biomarkers to predict which patients will benefit from antiangiogenic treatments.
Participant Demographics
The study involved patients with recurrent ovarian cancer, many of whom had platinum-resistant disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website